Abstract
Protein-protein interactions (PPIs) are receiving increasing interest, much sparked by the realization that they represent druggable targets. Recently, we successfully developed a peptidic inhibitor, RRYGTSKYQ("SKY" peptide), that shows high potential in vitro and in vivo to interrupt a PPI between the platelet-borne chemokine CCL5 and the neutrophil-derived granule protein HNP1. This PPI plays a vital role in monocyte adhesion, representing a key mechanism in acute and chronic inflammatory diseases. Here, we present extensive and detailed computational methods applied to develop the SKY peptide. We combined experimentally determined binding affinities (K-D) of several orthologs of CCL5 with HNP1 with in silico studies to identify the most likely heterodimeric CCL5 HNP1 complex which was subsequently used as a starting structure to rationally design peptidic inhibitors. Our method represents a fast and simple approach that can be widely applied to determine other protein protein complexes and moreover to design inhibitors or stabilizers of protein-protein interaction.
Dokumententyp: | Zeitschriftenartikel |
---|---|
Fakultät: | Medizin |
Themengebiete: | 600 Technik, Medizin, angewandte Wissenschaften > 610 Medizin und Gesundheit |
ISSN: | 0022-2623 |
Sprache: | Englisch |
Dokumenten ID: | 43618 |
Datum der Veröffentlichung auf Open Access LMU: | 27. Apr. 2018, 08:04 |
Letzte Änderungen: | 04. Nov. 2020, 13:18 |